Probiotics in the add-on treatment of pharyngotonsillitis: a clinical experience
I La Mantia,M Gelardi,L Drago,S E Aragona,G Cupido,C Vicini,C Berardi,G Ciprandi,Italian Study Group on Upper Respiratory Infections: Albanese G, Anni A, Antoniacomi G, Artoni S,
Asprella G, Azzaro R, Azzolin A, Balduzzi A, Barbarino I, Berardi C, Bertetto BI, Bianchi A, Bianco N,
Bonanno A, Bordonaro C, Brindisi AM, Bucolo S, Bulzomì AG, Caligo G, Capaccio P, Capelli M, Capone A,
Carboni S, Carluccio G, Casaula M, Cassano M, Cavaliere M, Ciabattoni A, Conti A, Cordier A, Cortellessa F,
Costanzo M, Cupido F, D’Ascanio L, Danza C, D’Auria C, De Ciccio M, De Luca C, D’Emila M, Dessi R,
Di Lullo A, D’Urso M, Falcetti S, Falciglia R, Fera G, Ferrari G, Ferraro SM, Fini O, Fiorella M, Floriddia A,
Asprea F, Fusco C, Fuson R, Gallo A, Gambardella T, Gambardella G, Giangregorio F, Gramellini G, Ierace M,
Ingria F, La Paglia A, Lanza L, Lauletta R, Lavazza P, Leone M, Lovotti P, Luperto P, Maniscalco F,
Marincolo I, Martone R, Melis A, Messina A, Milone V, Mirra N, Montanaro SC, Muià F, Nacci A, Nardello E,
Paderno L, Padovani D, Palma A, Paoletti M, Pedrotti I, Petrillo F, Piccolo M, Pinto P, Policarpo M, Raguso M,
Ranieri A, Romano G, Rondinelli M, Russo C, Scotto Di Santillo L, Sequino G, Serraino EM, Spahiu I, Spanò G,
Stabile C, Stagni G, Stellin M, Tassi S, Tomacelli G, Tombolini A, Valenzise V, Zirone A
Abstract:Pharyngotonsillitis is a common disease, mainly characterized by a sore throat. It may be classified as acute or chronic, based on duration. The diagnosis is usually performed on the clinical ground, and antibiotic therapy is frequently used in clinical practice. However, antibiotics frequently induce intestinal dysbiosis associated with some clinical problems. Therefore, probiotics are commonly prescribed in patients treated with antibiotics. The current clinical experience was conducted in patients with pharyngotonsillitis and treated with antibiotics. A one-month course of a probiotic mixture (Abincol® containing Lactobacillus plantarum LP01 (1 billion of living cells), Lactobacillus lactis subspecies cremoris LLC02 (800 million of living cells), and Lactobacillus delbrueckii subspecies delbrueckii LDD01 (200 million of living cells), was prescribed in the Group A, and was compared with no add-on treatment, such as the Group B. Patients were evaluated at baseline (T0), at the end of antibiotic treatment (T1), at the end of probiotic course (T2), and at the end of 3-month follow-up (T3). Globally, 1118 outpatients were enrolled. Acute pharyngotonsillitis affected 795 subjects: 396 in Group A and 399 in Group B. Chronic pharyngotonsillitis affected 323 outpatients: 158 in Group A and 165 in Group B. All patients were usually treated with a 7-10-day course of antibiotic therapy. In patients with acute pharyngotonsillitis, the probiotic mixture significantly reduced the duration of all the symptoms (p<0.001 for all), except for the urinary tract infection, associated with antibiotic therapy which was already at the end of the antibiotic cycle (T1). The intergroup analysis showed that patients with chronic pharyngotonsillitis in Group A had significantly less tiredness, pain, and malaise (p<0.001 for all) than patients in Group B at T1. The probiotic course reduced the possible clinical relapse, and the use of additional medications at T2 and T3 in patients with both acute and chronic pharyngotonsillitis. In conclusion, the present clinical experience demonstrated that a probiotic mixture containing Lactobacillus plantarum LP01, Lactobacillus lactis subspecies cremoris LLC02, and Lactobacillus delbrueckii, was able to quickly reduce symptoms, possible relapse, and use of additional medications, associated with antibiotic therapy, in patients with both acute and chronic pharyngotonsillitis.